Back to today’s briefing

Story perspectives

EMA Approves 114 Medicines, Including Breakthrough Alzheimer’s Treatment

1/17/2025

45 5

Summary

Story summary

In 2024, the EMA greenlit 114 medicines for marketing, featuring 46 groundbreaking active substances. Among them are the first-ever treatment for early Alzheimer’s, a revolutionary needle-free adrenaline, and innovative antibiotics. With 28 cancer therapies leading the charge, this report underscores significant strides in public health and the commitment to safety for authorized medicines across the EU.

1 of 1

Story summary

In 2024, the EMA greenlit 114 medicines for marketing, featuring 46 groundbreaking active substances. Among them are the first-ever treatment for early Alzheimer’s, a revolutionary needle-free adrenaline, and innovative antibiotics. With 28 cancer therapies leading the charge, this report underscores significant strides in public health and the commitment to safety for authorized medicines across the EU.